AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Autologous Stem Cell Transplantation
Interventions
DRUG

G-CSF plus plerixafor

Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2\*10\^6 CD34+ cells/kg were collected.

Trial Locations (8)

30342

Blood & Marrow Transplant Group of Georgia, Atlanta

39216

University of Mississippi Medical Center, Div of Hematology, Jackson

64111

Kansas City Cancer Centers, Kansas City

91010

City of Hope National Medical Center', Duarte

33612-9497

H. Lee Moffitt Cancer Center, Tampa

07601

Hackensack University Medical Center, Hackensack

23298-0037

Virginia Commonwealth University - Massey Cancer Center, Richmond

53792-5156

University of Wisconsin, Blood and Bone Marrow Transplant, Madison

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00396331 - AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts | Biotech Hunter | Biotech Hunter